Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus

Background: Sodium-glucose cotransporter 2 (SGLT2) inhibition has been shown to reduce cardiovascular mortality and preserve kidney function in patients with type 2 diabetes. Kidney transplant recipients with diabetes demonstrate increased risk and accelerated progression of micro- and macrovascular...

Full description

Bibliographic Details
Main Authors: Moritz Mahling, Anja Schork, Silvio Nadalin, Andreas Fritsche, Nils Heyne, Martina Guthoff
Format: Article
Language:English
Published: Karger Publishers 2019-08-01
Series:Kidney & Blood Pressure Research
Subjects:
Kidney transplantation
Diabetes mellitus
Sodium-glucose cotransporter 2 inhibition
Empagliflozin
Renal and cardiovascular endpoints
Online Access:https://www.karger.com/Article/FullText/501854

Internet

https://www.karger.com/Article/FullText/501854

Similar Items